Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 28, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial statements or performance metrics.
Material Changes
The filing details specific share movements within the SmithKline Beecham Employee Benefit Trust ("the Trust") on two dates:
- March 14, 2007: 369 Ordinary shares were sold at GBP 14.23 per share, and 515 Ordinary shares were transferred to participants in the Bonus Investment Plan.
- March 22, 2007: 1,479 Ordinary shares were sold at GBP 14.14 per share, and 1,809 Ordinary shares were transferred to participants.
These transactions were notified to the Company on March 27, 2007.
Management Commentary and Risks
The filing notes that the Trust is a discretionary fund for non-US employees and former employees. Director Mr. J S Heslop holds an interest in the shares held in the fund in the same capacity as other eligible employees. The notification complies with Disclosure Rule 3.1.4R(1)(b). No broader management outlook, risks, or contingencies are discussed in this specific filing.
Investor Verification Points
- Verify the total volume of shares sold versus transferred within the Trust during the reporting period.
- Confirm the specific share prices (GBP 14.23 and GBP 14.14) against market data for the respective transaction dates.
- Review the full composition of the SmithKline Beecham Employee Benefit Trust to understand the scope of Director J S Heslop's interest.